NCT00020371 2024-03-04
BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy
National Cancer Institute (NCI)
Phase 1 Completed
Clinical Trials
9 trialsNCT00879086 2023-06-22
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT00082433 2020-11-02
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
R-Pharm
Phase 3 Completed
NCT01416389 2019-09-18
A Study of LY2523355 in Participants With Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00207129 2017-01-30
Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies
R-Pharm
Phase 1 Completed
NCT00309049 2017-01-30
Ixabepilone Administered as an Enteric Coated Formulation.
R-Pharm
Phase 1/2 Completed
NCT01075100 2016-12-07
Ixabepilone + Carboplatin Metastatic Breast Cancer
US Oncology Research
Phase 2 Completed
NCT00362830 2016-09-19
A Study of the Alternative Administration of Ixabepilone and Vinflunine
Bristol-Myers Squibb
Phase 1 Completed
NCT00422097 2016-03-10
A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
R-Pharm
Phase 1 Completed